Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | TACR3 | P29371 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3748127 | 1.00 | HSD11B1 (0.61) | HSD11B1MEN1KMT2ATACR3SLC6A2 | |
| SCHEMBL3748695 | 0.94 | TACR3 (0.61) | HSD11B1TACR3TMEM97SIGMAR1 | |
| SCHEMBL3746695 | 0.94 | TACR3 (0.61) | HSD11B1TACR3TMEM97SIGMAR1 | |
| SCHEMBL3738194 | 0.94 | TACR3 (0.56) | HSD11B1MEN1KMT2ATACR3SLC6A2 | |
| SCHEMBL3743318 | 0.94 | TACR3 (0.56) | HSD11B1MEN1KMT2ATACR3SLC6A2 | |
| SCHEMBL3752488 | 0.89 | TACR3 (0.75) | HSD11B1MEN1KMT2ATACR3 | |
| SCHEMBL3743958 | 0.89 | TACR3 (0.58) | HSD11B1MEN1KMT2ATACR3SLC6A2 | |
| SCHEMBL3747103 | 0.89 | TACR3 (0.75) | HSD11B1MEN1KMT2ATACR3 | |
| SCHEMBL3748225 | 0.89 | TACR3 (0.58) | HSD11B1MEN1KMT2ATACR3SLC6A2 | |
| SCHEMBL2479971 | 0.84 | TACR3 (0.82) | TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834008-B2 | neurokinin receptor 3 (NK3) antagonists; psychological disorders, inflammatory bowel disease, asthma, ischemia, Parkinson's disease; e.g. (1S,2R)-2-(4-Acetylamino-4-phenyl-piperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)-cyclopropanecarboxylic acid, benzyl-methyl-amide | H. LUNDBECK A/S (DK) | 2010-11-16 | — | — | US | disclosed |
| US-20060281746-A1 | Cyclopropyl derivatives as nk3 receptor antagonists | H. LUNDBECK A/S (DK) | 2006-12-14 | — | — | US | disclosed |
| EP-1656349-A1 | CYCLOPROPYL DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | H. Lundbeck A/S (DK) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005016884-A9 | CYCLOPROPYL DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | LUNDBECK & CO AS H (DK) | 2006-03-16 | — | — | WO | disclosed |
| WO-2005016884-A1 | CYCLOPROPYL DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | H. LUNDBECK A/S (DK) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281746-A1 | Cyclopropyl derivatives as nk3 receptor antagonists | TACR2, SLC6A3, TACR1 | HSD11B1 1217/4885MEN1 3125/4885KMT2A 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.